LNRRIL6, a novel long noncoding RNA, protects colorectal cancer cells by activating the IL‐6–STAT3 pathway

Abstract

Long noncoding RNAs (lncRNAs) are emerging as critical regulators of cancer. There is a comparable number of lncRNAs to protein‐coding genes, but the expression patterns, functions, and molecular mechanisms of most lncRNAs in colorectal cancer (CRC) remain unclear. In this study, we report the identification of a novel lncRNA, named long noncoding RNA regulating IL‐6 transcription (LNRRIL6), which is upregulated in CRC tissues and cell lines. Increased LNRRIL6 expression is associated with aggressive clinicopathological characteristics and poor prognosis of CRC patients. Functional experiments showed that enhanced expression of LNRRIL6 promotes CRC cell proliferation and survival in vitro and CRC tumor growth in vivo. Conversely, depletion of LNRRIL6 inhibits CRC cell proliferation and survival in vitro and CRC tumor growth in vivo. Mechanistically, we revealed that LNRRIL6 physically binds to the IL‐6 promoter, thereby increasing IL‐6 transcription, inducing IL‐6 autocrine signaling, and activating the IL‐6/STAT3 pathway. The expression of IL‐6 is positively associated with that of LNRRIL6 in CRC tissues. Blocking the IL‐6/STAT3 pathway using the FDA‐approved IL‐6‐receptor antagonist antibody, tocilizumab, abolished the oncogenic role of LNRRIL6 in CRC. Taken together, these findings identify a novel lncRNA, LNRRIL6, that promotes CRC cell survival through activation of the IL‐6/STAT3 pathway and suggest that LNRRIL6 may be a potential prognostic biomarker and therapeutic target for CRC.

KLHDC7B-DT aggravates pancreatic ductal adenocarcinoma development via inducing cross-talk between cancer cells and macrophages

“…IL-6/STAT3 signaling has critical oncogenic roles in several cancers [39,54]. In this study, we found that via activating IL-6 transcription, up-regulating IL-6 expression and secretion, KLHDC7B-DT activated IL-6/STAT3 signaling in an autocrine manner.…”

Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation

“…Contrary to lnc-DILC and TSLNC8 , lncRNA regulating IL-6 transcription ( LNRRIL6 ) demonstrated an oncogenic role by promoting IL-6/STAT3 axis and its downstream molecules including cell division cycle 25 A (CDC25A), cyclin D1, survivin, and B-cell lymphoma 2 (BCL2). Relatively, injection of LNRRIL6 overexpression cells into athymic nude mice induced tumor growth [ 78 ]. Strikingly, lncRNA metastasis associated lung adenocarcinoma transcript 1 ( MALAT1 ), also known as NEAT2 , has indicated a dual role regarding inflammation responses and cytokine secretion especially IL-6 in different signaling pathways.…”

Identification of intestinal flora-related key genes and therapeutic drugs in colorectal cancer

“…Accordingly, IL6R has been proposed as a promising target for CRC treatment. IL6R antagonist antibody, tocilizumab, could significantly reduce viability and enhance the apoptosis of CRC cells by blocking the IL-6/STAT3 pathway [ 39 ].…”